• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • e‑newsletter
    • e‑newsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

Growing controversy over role of FDA and Medicare in promoting anti-amyloid drugs given limited benefit, high cost, severe side-effects

June 21, 2023 by SharpBrains

The War Over Whether Medicare Should Pay For The New Anti-Alzheimer’s Drugs (Forbes):

The pow­er­ful Alzheimer’s Dis­ease lob­by is fight­ing a mul­ti-bil­lion-dol­lar bat­tle on two fronts. It is qui­et­ly try­ing to lim­it restric­tions the Food and Drug Admin­is­tra­tion puts on the use of new drugs aimed at slow­ing the pro­gres­sion of the brain dis­ease. And it is pub­licly press­ing Medicare to pay for the wide­spread use of the mon­o­clon­al anti­bod­ies FDA already has con­di­tion­al­ly approved as well as oth­ers in the pipeline.

While the FDA approves drugs for use, it doesn’t decide who pays for them. And, for now, the Cen­ters for Medicare and Med­ic­aid Ser­vices (CMS) per­mits Medicare to pay for these med­ica­tions under only lim­it­ed circumstances…

While these deci­sions should be based on sci­ence, the Alzheimer’s lob­by is rolling out its polit­i­cal big guns. Mem­bers of Con­gress are demand­ing that Medicare pay. Advo­cates allege racial bias in Medicare’s reluc­tance to cov­er the drugs. Why? Because they say tri­als and even reg­istries are less like­ly to include Black and His­pan­ic patients as well as those liv­ing in rur­al communities.

In one unusu­al advo­ca­cy move, drug­mak­er Eli Lil­ly, which has applied for FDA approval of its own mon­o­clon­al anti­body, pur­chased what effec­tive­ly was a two-hour infomer­cial pre­sent­ed by the online news ser­vice The Hill. It fea­tured law­mak­ers, researchers, and rep­re­sen­ta­tives of advo­ca­cy groups all urg­ing CMS to pay for these drugs. No researchers who ques­tioned the drug’s safe­ty or effi­ca­cy were interviewed.

Euro­pean Alzheimer’s experts uncon­vinced by new Eisai, Bio­gen drug (Reuters):

…In Europe, where cost-con­scious coun­tries rig­or­ous­ly weigh new drugs before adopt­ing their use, nine neu­rol­o­gists and researchers across six coun­tries told Reuters lecanemab is unlike­ly to be wide­ly used if approved. Their views under­pin ana­lyst esti­mates sug­gest­ing Europe will be a small mar­ket for the drug.

Some doc­tors said its effect on the dis­ease may not be clin­i­cal­ly mean­ing­ful enough when weighed against the risk of brain swelling, its like­ly high price, and lim­it­ed per­son­nel and resources to admin­is­ter twice month­ly infu­sions and mon­i­tor for brain swelling with MRI scans.

Does Medicare pay for Alzheimer’s drugs? The answer is com­pli­cat­ed and chang­ing (For­tune):

Typ­i­cal­ly, Medicare cov­ers what the FDA approves.

In April 2022, CMS decid­ed that Medicare would cov­er Adul­helm (cost: $28,200 a year, down from the ini­tial $56,000 price) and treat­ments like it only for ben­e­fi­cia­ries with Medicare Part B who are enrolled in a clin­i­cal tri­al approved by the agency or by the Nation­al Insti­tutes of Health…

In ear­ly June, CMS said that if the FDA grants tra­di­tion­al approval to drugs slow­ing the pro­gres­sion of Alzheimer’s, Medicare will cov­er the cost for qual­i­fy­ing ben­e­fi­cia­ries who also have a doc­tor par­tic­i­pat­ing in a spe­cial registry.

Some crit­ics think a reg­istry could be cum­ber­some for doc­tors and patients and might exclude patients in rur­al and under­served areas.

Ongoing petition by a number of scientists and doctors:

Lecanemab is nei­ther safe nor effec­tive for Alzheimer’s patients: Against the FDA approval — Sign the Peti­tion! https://t.co/ahkiJts8hj via @Change

In my opin­ion we are going down a dan­ger­ous road. We need to con­sult our maps and re-ori­ent our­selves. Please con­sid­er signing.

— Karl Her­rup (@KarlHerrup) June 18, 2023

News in Context:

  • Should doc­tors pre­scribe lecanemab (Leqem­bi) to women? The answer, giv­en avail­able evi­dence, is prob­a­bly No

Share this:

  • Tweet
  • Email
  • Print
  • Red­dit
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health Tagged With: Alzheimer's experts, Alzheimer’s Disease, Anti-Alzheimer’s Drugs, Biogen, brain swelling, Eisai, europe, FDA, lecanemab, Medicare

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Subscribe to our e-newsletter

* indicates required

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2023 SharpBrains. All Rights Reserved - Privacy Policy